Valuation: Ainos, Inc.

Market Cap 13.18M 11.54M 10.66M 9.95M 18.73M 1.25B 19.16M 128M 49.5M 615M 49.51M 48.42M 2.13B P/E 2024
-0.29x
P/E 2025 -0.47x
Enterprise Value 23.77M 20.81M 19.21M 17.94M 33.77M 2.25B 34.54M 231M 89.24M 1.11B 89.25M 87.29M 3.85B EV / Sales 2024
701x
EV / Sales 2025 162x
Free-Float
33.62%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 56 2021-04-14
Director of Finance/CFO 54 2024-03-14
Director TitleAgeSince
Director/Board Member 49 2021-04-14
Director/Board Member 54 2021-04-14
Director/Board Member 42 2021-04-14
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-10.00% - - 12.74M
-1.29%+9.00%+24.04%-0.73% 191B
+0.31%-0.20%-23.93%+21.92% 143B
-1.74%+8.81%-3.03%-17.89% 139B
-1.70%-4.00%-59.19%-18.65% 65.74B
+0.44%+4.37%+16.58%+0.82% 52.27B
-0.47%-0.50%-27.38%-32.98% 43.55B
-2.34%+4.54%+11.46%+14.14% 38.41B
-1.48%+3.78%+4.67%+43.28% 36.76B
-1.08%+5.62%-12.54%-15.73% 29.91B
Average -0.93%+4.59%-7.70%-0.65% 82.17B
Weighted average by Cap. -0.99%+5.58%-4.39%-0.59%

Financials

2024 2025
Net sales 20.73K 18.15K 16.76K 15.65K 29.45K 1.96M 30.13K 202K 77.84K 967K 77.85K 76.14K 3.36M 124K 109K 100K 93.72K 176K 11.74M 180K 1.21M 466K 5.79M 466K 456K 20.11M
Net income -14.86M -13.01M -12.01M -11.22M -21.12M -1.41B -21.6M -145M -55.81M -693M -55.82M -54.59M -2.41B -14.77M -12.93M -11.94M -11.15M -20.99M -1.4B -21.47M -144M -55.47M -689M -55.47M -54.25M -2.39B
Net Debt 8.11M 7.1M 6.55M 6.12M 11.52M 766M 11.78M 78.86M 30.44M 378M 30.45M 29.78M 1.31B 10.58M 9.27M 8.55M 7.99M 15.04M 1B 15.38M 103M 39.74M 494M 39.74M 38.87M 1.71B
Logo Ainos, Inc.
Ainos, Inc. is a dual-platform AI and biotech company advancing SmellTech and immune therapeutics. Its AI Nose platform and smell language model (SML) digitize scent into Smell ID, a machine-readable data, powering applications across robotics, smart factories, and healthcare. It is also developing VELDONA, an oral low-dose interferon therapy targeting rare diseases, autoimmune diseases, infectious diseases, and animal health. Its pipeline includes drug candidates for treating oral warts for human immunodeficiency virus seropositive patients, Sjogren’s syndrome, and feline chronic gingivostomatitis, a cat oral infection. Its product pipeline includes VELDONA Pet, VELDONA human drugs, AI Nose - NISD co-development, AI Nose industrial and robotics application, VOC POCT, VOC POCT Ainos Pen, VOC POCT CHS430, and Synthetic RNA (SRNA). VOC POCT-Ainos Pen is a device intended to be a cloud-connected, multipurpose, portable breath analyzer that is intended to monitor health conditions.
Employees
-